STOCK TITAN
  1. Home
  2. Sec-filings
  3. NSRX
  4. [EFFECT] Nasus Pharma Ltd SEC Filing

[EFFECT] Nasus Pharma Ltd SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 13, 2026 4:30 P.M.
Form: F-1
CIK: 0002029039
Company Name: Nasus Pharma Ltd
File Number: 333-293950

Source: View Original Filing on SEC EDGAR

Nasus Pharma Ltd.

NYSE:NSRX

View NSRX Stock Overview →

NSRX Rankings

#5511 Ranked by Market Cap
N/A Ranked by Dividends

NSRX Latest News

Mar 16, 2026
Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold
Mar 9, 2026
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
Mar 9, 2026
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
Feb 20, 2026
Nasus Pharma to Participate in Upcoming Investor Conferences
Feb 17, 2026
Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026

NSRX Latest SEC Filings

Mar 16, 2026
[6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)
Mar 6, 2026
[6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)
Mar 4, 2026
[6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)
Mar 2, 2026
[F-1] Nasus Pharma Ltd Foreign Issuer IPO Registration
Feb 23, 2026
[6-K] Nasus Pharma Ltd Current Report (Foreign Issuer)

NSRX Stock Data

58.55M
5.85M
Drug Manufacturers - General
Healthcare
Link
Israel
Tel Aviv-Yafo